$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials
[Lowest Price Guaranteed: $2,995]

Published by Current Partnering: 01 Oct 2016 | 367 | In Stock
Related Topics: Vaccine

Introduction

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.


This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2010

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 600 infectious vaccines deal records

Identify the most active infectious vaccine dealmakers since 2010

The leading infectious vaccines deals by value since 2010

Includes adjuvant deals and alliances since 2010


In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific infectious therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in Infectious Vaccines dealmaking

    2.1. Introduction

    2.2. Infectious Vaccines partnering over the years

    2.3. Most active Infectious Vaccines dealmakers

    2.4. Infectious Vaccines partnering by deal type

    2.5. Infectious Vaccines partnering by therapy area

    2.6. Deal terms for Infectious Vaccines partnering

    2.6.1 Infectious Vaccines partnering headline values

    2.6.2 Infectious Vaccines deal upfront payments

    2.6.3 Infectious Vaccines deal milestone payments

    2.6.4 Infectious Vaccines royalty rates

    Chapter 3 – Leading Infectious Vaccines deals

    3.1. Introduction

    3.2. Top Infectious Vaccines deals by value

    Chapter 4 – Most active Infectious Vaccines dealmakers

    4.1. Introduction

    4.2. Most active Infectious Vaccines dealmakers

    4.3. Most active Infectious Vaccines partnering company profiles

    Chapter 5 – Infectious Vaccines contracts dealmaking directory

    5.1. Introduction

    5.2. Infectious Vaccines contracts dealmaking directory

    Chapter 6 – Infectious Vaccines dealmaking by technology type

    Chapter 7 – Partnering resource center

    7.1. Online partnering

    7.2. Partnering events

    7.3. Further reading on dealmaking

    Appendices

    Appendix 1 – Infectious Vaccines deals by company A-Z

    Appendix 2 – Infectious Vaccines deals by stage of development

    Discovery

    Preclinical

    Phase I

    Phase II

    Phase III

    Regulatory

    Marketed

    Formulation

    Appendix 3 – Infectious Vaccines deals by deal type

    Asset purchase

    Assignment

    Bigpharma outlicensing

    Co-development

    Collaborative R&D

    Co-market

    Co-promotion

    CRADA

    Development

    Distribution

    Equity purchase

    Evaluation

    Grant

    Joint venture

    Licensing

    Manufacturing

    Marketing

    Option

    Promotion

    Research

    Settlement

    Spin out

    Sub-license

    Supply

    Technology transfer

    Termination

    Appendix 4 – Infectious Vaccines deals by therapy area

    Appendix 5 – Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    Table of figures

    Figure 1: Infectious Vaccines partnering since 2010

    Figure 2: Active Infectious Vaccines dealmaking activity– 2010 to 2016

    Figure 3: Infectious Vaccines partnering by deal type since 2010

    Figure 4: Infectious Vaccines partnering by disease type since 2010

    Figure 5: Infectious Vaccines deals with a headline value

    Figure 6: Infectious Vaccines deals with an upfront value

    Figure 7: Infectious Vaccines deals with a milestone value

    Figure 8: Infectious Vaccines deals with a royalty rate value

    Figure 9: Top Infectious Vaccines deals by value since 2010

    Figure 10: Most active Infectious Vaccines dealmakers 2010 to 2016

    Figure 11: Online partnering resources

    Figure 12: Forthcoming partnering events

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

367 | CP22061

Number of Pages

457

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials
Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseas...
01 Oct 2016 by Current Partnering USD $3,495 More Info
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryThe National Institute of Allergy and Infectious Diseases (NIAID) a subsidiary of National In...
12 May 2016 by Global Data USD $250 More Info
Infectious Disease Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInfectious Disease Research Institute (IDRI) is a nonprofit healthcare institute that provide...
06 May 2016 by Global Data USD $250 More Info
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryThe National Institute of Allergy and Infectious Diseases (NIAID), a subsidiary of National I...
17 Mar 2016 by Global Data USD $250 More Info
Infectious Disease Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInfectious Disease Research Institute (IDRI) is a healthcare institute that provides various ...
10 Mar 2016 by Global Data USD $250 More Info
Italy Infectious Diagnostics Market Outlook to 2021
Italy Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "Italy Infectious...
04 Sep 2015 by Global Data USD $2,500 More Info
Spain Infectious Diagnostics Market Outlook to 2021
Spain Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "Spain Infectious...
04 Sep 2015 by Global Data USD $2,500 More Info
United Kingdom Infectious Diagnostics Market Outlook to 2021
United Kingdom Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "United ...
01 Sep 2015 by Global Data USD $2,500 More Info
France Infectious Diagnostics Market Outlook to 2021
France Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "France Infectio...
01 Sep 2015 by Global Data USD $2,500 More Info
Germany Infectious Diagnostics Market Outlook to 2021
Germany Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "Germany Infect...
01 Sep 2015 by Global Data USD $2,500 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...